miRNA-182水平與宮頸癌患者臨床病理特征及預后的關系

［摘 要］目的 探討miRNA-182水平與宮頸癌患者臨床病理特征及預后的關系。方法 選擇2021年2月至2023年6月在海南醫學院第一附屬醫院治療的112例宮頸癌患者為研究對象，根據研究對象180天隨訪過程中有無死亡這一不良結局為判斷終點，分為預后良好組（78例）和預后不良組（34例）。對不同miRNA-182水平患者進行臨床特征比較，分析不同miRNA-182水平患者預后情況，研究患者miRNA-182水平與預后不良發生概率的劑量反應關系，進行miRNA-182水平與預后的決策曲線分析（DCA）。結果 與低水平miRNA-182組相比，中高水平組患者年齡較大，吸煙史、糖尿病史、國際婦產科聯合會（FIGO）腫瘤分期Ⅲ～Ⅳ期、鱗狀細胞癌、輔助治療給藥、淋巴結轉移占比較高，飲酒史、陰道浸潤占比較低，差異均具有統計學意義（χ²/F值介于3.650～15.118之間，P＜0.05）；與預后良好組相比，預后不良組患者miRNA-182水平較高，差異具有統計學意義（t＝2.652，P＜0.05）；Cox回歸模型顯示低、中等水平組患者預后不良風險均低于高水平組（HR值介于0.125～0.566之間，P＜0.05）；劑量反應關系結果顯示miRNA-182水平與預后不良呈顯著正相關性；DCA曲線分析結果顯示，高風險閾值在1%～70%內取值越小，凈獲益率越高，臨床意義越大。結論 miRNA-182水平對宮頸癌患者的預后有良好的預測價值，值得臨床推廣。

［關鍵詞］miRNA-182；宮頸癌；臨床病理特征；預后

Doi：10.3969/j.issn.1673-5293.2025.03.004

［中圖分類號］R179""" ［文獻標識碼］A

［文章編號］1673-5293（2025）03-0021-09

Relationship between miRNA-182 level and clinicopathological features

and prognosis of patients with cervical cancer

GAO Fei¹，WANG Yongcun²，YIN Jilai¹，WANG Daping¹

（1.Department of Clinical Laboratory，The First Affiliated Hospital of Hainan Medical College，Hainan Haikou 570105，

China;2.Tumor Center，The Affiliated Hospital of Guangdong Medical University，Guangdong Zhanjiang 524001，China）

［Abstract］ Objective To investigate the relationship between miRNA-182 levels and the clinical pathological characteristics and prognosis of cervical cancer patients. Methods A total of 112 cervical cancer patients treated at the First Affiliated Hospital of Hainan Medical College from February 2021 to June 2023 were selected as the study subjects，and they were divided into good prognosis group （78 cases） and poor prognosis group （34 cases） according to the adverse outcome of death during the 180-day follow-up of the study subjects.The clinical characteristics of patients with different miRNA-182 levels were compared，the prognosis of patients with different miRNA-182 levels was analyzed，the dose-response relationship between miRNA-182 levels and the probability of adverse prognosis was studied，and the decision curve analysis （DCA） between miRNA-182 levels and prognosis was analyzed. Results Compared with the low-level miRNA-182 group，the patients in the middle-to-high-level group were older，with a higher proportion of smoking history，diabetes history，International Federation of Obstetrics and Gynecology （FIGO） tumor stage Ⅲ-Ⅳ，squamous cell carcinoma，adjuvant therapy administration，lymph node metastasis，alcohol history and vaginal invasion，and the differences were statistically significant （χ²/F values ranging from 3.650 to 15.118，P＜0.05）.Compared with the good prognosis group，the miRNA-182 level was higher in the poor prognosis group，and the difference was statistically significant （t＝2.652，P＜0.05）.The Cox regression model showed that the risk of poor prognosis in the low- and middle-level groups was lower than that in the high-level group （HR values ranging from 0.125 to 0.566，P＜0.05）.The results of dose-response relationship showed that miRNA-182 level was significantly positively correlated with poor prognosis.The results of DCA curve analysis showed that the smaller the high-risk threshold within 1%～70%，the higher the net benefit rate and the greater the clinical significance. Conclusion The level of miRNA-182 has a good predictive value for the prognosis of cervical cancer patients，which is worthy of clinical promotion.

［Key words］ "miRNA-182;cervical cancer;clinicopathological feature;prognosis

宮頸癌是全球女性常見癌癥之一，2020年全球發病率為13.3/10萬人^［1］。每10例病例中就有8例發生在低收入和中等收入國家——這種差異是由癌癥預防和治療機會不平等造成的^［2］。此外，約有342 000例宮頸癌死亡，占惡性腫瘤女性死亡人數的7.7%。……